Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221945 · ClinicalTrials.gov registry record · Phase 3
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,060
- Enrollment target
NCT04221945 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 1,060 participants.
The verdict
NCT04221945, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,060 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival. Once the study objectives have been met or the study has ended, participants will be discontinued from this study and will be enrolled in an extension study to continue protocol-defined assessments and treatment.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Cisplatin
- RADIATION Brachytherapy
- RADIATION External Beam Radiotherapy (EBRT)
- DRUG Placebo for pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,060 participants |
| Start Date | 2020-05-12 |
| Est. Completion | 2026-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04221945
The ClinicalTrials.gov registry entry for NCT04221945 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,060 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04221945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04221945 about?
NCT04221945 is a clinical study titled "Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)". The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradioth...
What is the current status of trial NCT04221945?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,060 participants. The study started on 2020-05-12. Estimated completion is 2026-01-26.
What interventions are being tested in trial NCT04221945?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cisplatin (DRUG), Brachytherapy (RADIATION), External Beam Radiotherapy (EBRT) (RADIATION), Placebo for pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT04221945?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.